Promotie onderzoek

Klinische farmacologie

Antimicrobiele therapie bij kinderen in Afrika

Universiteit Radboud UMC Nijmegen
Promovendus Tom Jacobs
Promoters David Burger
Co-Promoters ds Angela Colbers
Jaar 2019 - 2023

Onderzoek naar de farmacokinetiek van antiretrovirale middelen, tuberculose medicatie en valganciclovir in HIV-geinfecteerde kinderen.

Farmacokinetiek en -dynamiek

The impact of continuous renal replacement therapy and hyperinflammation on the pharmacokinetics in intensive care unit patients

Universiteit Erasmus Medisch Centrum Rotterdam
Promovendus Tim Smeets
Promoters prof. dr. Birgit Koch prof. dr. Diederik Gommers
Co-Promoters ds dr. Nicole G.M. Hunfeld dr. Henrik Endeman
Jaar 2021-2023

To study the impact of inflammation on midazolam pharmacokinetics in critically ill covid-19 patients.
To study the impact of continuous renal replacement therapy on target attainment and pharmacokinetics of drugs in critically ill patients.

Medicatieveiligheid

Sexual adverse drug reactions

Universiteit Leiden Universitair Medisch Centrum
Promovendus Rineke Gordijn
Promoters Prof Dr Henk-Jan Guchelaar
Co-Promoters ds Dr Martina Teichert
Jaar 2020-2022

Productzorg en bereiding

3D printing of pharmaceutical preparations

Universiteit Leiden Universitair Medisch Centrum
Promovendus Iris Lafeber
Promoters Prof Dr Henk-Jan Guchelaar
Co-Promoters ds Dr Kirsten Schimmel
Jaar 2020-2024

Klinische farmacologie

Retroperitoneal fibrosis

Universiteit Leiden Universitair Medisch Centrum
Promovendus Hardjit Kharagjitsing
Promoters Prof Dr Teun van Gelder
Jaar 2020-2023

Farmacogenetica

Treatment and genetics of RA

Universiteit Leiden Universitair Medisch Centrum
Promovendus Frank Eektimmerman
Promoters Prof Dr Henk-Jan Guchelaar
Co-Promoters ds Dr Jesse Swen
Jaar 2015-2022

Farmacokinetiek en -dynamiek

Computational modeling of tumor growth and clonal evolution

Universiteit Leiden Universitair Medisch Centrum
Promovendus Anyue Yin
Promoters Prof Dr Henk-Jan Guchelaar
Co-Promoters ds Dr Dirk Jan Moes
Jaar 2017-2022

Use population PK/PD modeling approach and consider evolving resistance development to better understand the development of drug resistance in anti-cancer treatments and to optimize and individualize anti-cancer treatment.